A BILL 
To mitigate the effects of the COVID–19 pandemic on incen-
tives under the Federal Food, Drug, and Cosmetic for 
the development of orphan drugs, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Orphan Drug COVID– 
4
19 Mitigation Act of 2022’’. 
5
16:02 Aug 17, 2022
H8641
2 
•HR 8641 IH
SEC. 2. MITIGATION OF EFFECTS OF COVID–19 PANDEMIC 
1
ON ORPHAN-DRUG DEVELOPMENT INCEN-
2
TIVES. 
3
(a) IN GENERAL.—In the case of a covered orphan 
4
drug, each of the following exclusivity periods is deemed 
5
to be extended by 180 days, so long as such period is not 
6
expired: 
7
(1) The 12-year period referred to in subpara-
8
graph (A) of section 351(k)(7) of the Public Health 
9
Service Act (42 U.S.C. 262(k)(7)). 
10
(2) The 5-year period referred to in subsection 
11
(c)(3)(E)(ii) and subsection (j)(5)(F)(ii) of section 
12
505 of the Federal Food, Drug, and Cosmetic Act 
13
(21 U.S.C. 355). 
14
(3) The 3-year period referred to in each of 
15
clauses (iii) and (iv) of subsection (c)(3)(E) and 
16
clauses (iii) and (iv) of subsection (j)(5)(F) of sec-
17
tion 505 of the Federal Food, Drug, and Cosmetic 
18
Act (21 U.S.C. 355). 
19
(4) The 7-year period referred to in section 
20
527(a) of the Federal, Food, Drug, and Cosmetic 
21
Act (21 U.S.C. 360cc). 
22
(5) In the case of a covered orphan drug with 
23
one or more certifications specified in clauses (ii), 
24
(iii), and (iv) of section 505(b)(2)(A) of the Federal 
25
Food, 
Drug, 
and 
Cosmetic 
Act 
(21 
U.S.C. 
26
16:02 Aug 17, 2022
H8641
3 
•HR 8641 IH
355(b)(2)(A)), or in subclauses (II), (III), and (IV) 
1
of section 505(j)(2)(A) of such Act (21 U.S.C. 
2
355(j)(2)(A)), each corresponding patent-related ap-
3
proval-delay period (other than a patent for which 
4
the information required pursuant to subsection (b) 
5
or (c) of section 505 of the Federal Food, Drug, and 
6
Cosmetic Act (21 U.S.C. 355) has not been filed). 
7
(b) CONFORMING EXTENSIONS.—In addition to the 
8
periods extended under subsection (a) for a covered or-
9
phan drug, the following periods are each deemed to be 
10
extended by 180 days: 
11
(1) The 4-year period referred to in subpara-
12
graph (B) of section 351(k)(7) of the Public Health 
13
Service Act (42 U.S.C. 262(k)(7)). 
14
(2) The 4-year, 48-month, and 7 and one-half- 
15
year periods referred to in subsection (c)(3)(E)(ii) 
16
and subsection (j)(5)(F)(ii) of section 505 of the 
17
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
18
355). 
19
(c) DEFINITIONS.—In this section: 
20
(1) The term ‘‘covered orphan drug’’ means an 
21
orphan drug for which— 
22
(A) an application is submitted under sec-
23
tion 505(i) of the Federal Food, Drug, and 
24
Cosmetic Act (21 U.S.C. 355(i)) during the 
25
16:02 Aug 17, 2022
H8641
4 
•HR 8641 IH
COVID–19 emergency period (without regard 
1
to whether the same applicant has submitted 
2
such applications for the same drug before De-
3
cember 1, 2019, for a different rare disease or 
4
condition); 
5
(B) an application under section 505(b) of 
6
the Federal Food, Drug, and Cosmetic Act or 
7
under section 351(a) of the Public Health Serv-
8
ice Act (or a supplemental application, as the 
9
case may be) is approved pursuant to the inves-
10
tigational new drug application referred to in 
11
paragraph (1); and 
12
(C) there is no approved indication that is 
13
not for a rare disease or condition. 
14
(2) The term ‘‘corresponding patent-related ap-
15
proval delay period’’, with respect to a covered or-
16
phan drug, means the period ending with the last 
17
applicable date for the approval of an application 
18
within the meaning of subparagraph (A), (B), or (C) 
19
of section 505(c)(3) of the Federal, Food, Drug, and 
20
Cosmetic Act (21 U.S.C. 355(c)(3)), or clause (i), 
21
(ii), or (iii) of section 505(j)(5)(B) of such Act (21 
22
U.S.C. 355(j)(5)(B)), whichever applies pursuant to 
23
the applicable patent certification. 
24
16:02 Aug 17, 2022
H8641
5 
•HR 8641 IH
(3) The term ‘‘orphan drug’’ means a drug that 
1
the Secretary has designated as a drug for a rare 
2
disease or condition under section 526(a) of the 
3
Federal, Food, Drug, and Cosmetic Act (21 U.S.C. 
4
360bb(a)). 
5
(4) The term ‘‘COVID–19 emergency period’’ 
6
means the period beginning on December 1, 2019, 
7
and ending on the date that is not later than 120 
8
days before the date on which the emergency period 
9
(as defined in section 1135(g)(1)(B) of the Social 
10
Security Act (42 U.S.C. 1320b–5(g)(1)(B))) termi-
11
nates. 
12
(5) The term ‘‘rare disease or condition’’ has 
13
the meaning given such term in section 526 of the 
14
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
15
360bb). 
16
(d) EFFECTIVE DATE.—This section takes effect 
17
upon the date of the enactment of this Act, without regard 
18
to whether the Secretary has issued guidance or regula-
19
tions regarding the implementation of this Act. 
20
Æ 
03:35 Aug 18, 2022
H8641
